ABSTRACT
Es una revisión de algunos nuevos e importantes aspectos del eritema polimorfo. Se pasa revista a la etiología, patogenia, clínica, histopatología, diagnóstico y tratamiento. Se puntualiza con predilección en los agentes etiológicos y formas clínicas como los síndromes de stevens Johnson y lyell y sus asociaciones clínicas
Subject(s)
Humans , Erythema Multiforme/diagnosis , Erythema Multiforme/etiology , Erythema Multiforme/pathology , Erythema Multiforme/therapy , Stevens-Johnson Syndrome , Diagnosis, DifferentialABSTRACT
Es una revisión de algunos nuevos e importantes aspectos del eritema polimorfo. Se pasa revista a la etiología, patogenia, clínica, histopatología, diagnóstico y tratamiento. Se puntualiza con predilección en los agentes etiológicos y formas clínicas como los síndromes de stevens Johnson y lyell y sus asociaciones clínicas(AU)
Subject(s)
Humans , Erythema Multiforme/diagnosis , Erythema Multiforme/etiology , Erythema Multiforme/pathology , Erythema Multiforme/therapy , Stevens-Johnson Syndrome , Diagnosis, DifferentialABSTRACT
BACKGROUND: The exacerbation of porokeratosis of Mibelli associated with inmunosuppression has been well documented. MATERIALS AND METHODS: We describe the clinical and histologic data of three cases of HIV-infected patients, who developed porokeratosis following HIV-contact. RESULTS: The three reported patients were found to have the clinical and histologic features of porokeratosis of Mibelli. Either the exacerbation or development of the disease followed HIV infection. CONCLUSION: Although porokeratosis is not a disease indicative of AIDS, its flare-up or its presence in HIV-infected patients may serve as a marker of inmunodeficiency.
Subject(s)
HIV Infections/complications , Porokeratosis/complications , Adult , CD4 Lymphocyte Count , HIV Infections/immunology , Humans , Male , Porokeratosis/pathology , Skin/pathologyABSTRACT
A randomized, investigator-blind, parallel-group trial was conducted to compare the safety and efficacy of 0.1% mometasone furoate cream applied once daily with that of 0.1% betamethasone valerate cream applied twice daily in patients (n = 69) with allergic contact dermatitis, atopic dermatitis and other steroid-responsive dermatoses. After 3 day's treatment improvement in conditions averaged 38.2% and 39.3%, respectively, in the mometasone and betamethasone treatment groups, and after 21 days average improvements were 93.6% and 96.5%, respectively. The physicians' global evaluation of overall change in disease status and the patients' evaluation of treatment also indicated that the two treatment regimens produced comparable, rapid and progressive improvements in the patients' conditions, and no local side-effects were reported. It is concluded that mometasone furoate was as effective as betamethasone valerate in the treatment of a variety of steroid-responsive dermatoses, although mometasone furoate was applied only half as frequently.
Subject(s)
Anti-Inflammatory Agents/administration & dosage , Betamethasone/administration & dosage , Dermatitis, Atopic/drug therapy , Dermatitis, Contact/drug therapy , Pregnadienediols/administration & dosage , Administration, Cutaneous , Adolescent , Adult , Anti-Inflammatory Agents/adverse effects , Betamethasone/adverse effects , Drug Administration Schedule , Female , Glucocorticoids , Humans , Male , Mometasone Furoate , Ointments , Pregnadienediols/adverse effects , Random AllocationSubject(s)
Lichen Planus/drug therapy , Tretinoin/analogs & derivatives , Acitretin , Adult , Female , Humans , Male , Tretinoin/adverse effects , Tretinoin/therapeutic useABSTRACT
At present HL: should be considered a marker of immunodeficiency, though not necessarily associated with HIV infection. In eight patients with HL it was confirmed that this lesion, in male homosexuals, in a precursor and marker of AIDS. The diagnosis of HL warrant all efforts to protect the immune system and avoid progression to AIDS.
Subject(s)
Acquired Immunodeficiency Syndrome/complications , Leukoplakia, Oral/etiology , Adult , Humans , Leukoplakia, Oral/complications , Leukoplakia, Oral/pathology , MaleABSTRACT
Forty-five patients suffering from various genodermatoses and erythematous, scaling, non-psoriatic dermatoses were treated orally with the aromatic derivative of retinoic acid, Ro 10-9359 (Tigason). In the genodermatoses the best results were obtained in ichthyosis, keratodermias and Darier's disease (95.6% good to excellent). Among the erythematous scaling diseases, treatment was effective in lichen planus, parapsoriasis and pityriasis rubra pilaris (53.3% good to excellent results). In comparison with therapies previously employed Ro 10-9359 was more effective. No serious side-effects were noted.
Subject(s)
Etretinate/therapeutic use , Skin Diseases/drug therapy , Tretinoin/analogs & derivatives , Administration, Oral , Adolescent , Adult , Aged , Child , Child, Preschool , Drug Evaluation , Erythema/drug therapy , Etretinate/administration & dosage , Etretinate/adverse effects , Female , Humans , Male , Middle Aged , Skin Diseases/geneticsABSTRACT
In the study presented, an evaluation has been made of the results achieved in a group of 32 psoriatic patients treated with a derivative of the retinoid acid, i.e. Ro 10-9359, taken orally. The therapy used was considered highly favourable in 28 cases and favourable in 3. It is considered that the treatment is effective independently of the time of evolution and of the extension of seriousness of the disease with no effects on the visceral or humoral sectors. All the information included in the present study allows to assert that the treatment of psoriasis with this derivative of the retinoid acid represents a significant progress as compared with the corticoids or cythostatics therapy.
